Biological

Question 1

Locally advanced or metastatic PDL-1 positive EAC after progression on standard tx: Pembrolizumab as per KEYNOTE-028 Study: % of responding and duration of response?

Answer 1

PR: 13% (median time to PR 8 wks) median DOR: >64m; with 2/3 ongoing response

SD: 13% - median DOR 25m

Question 2

Locally advanced or metastatic PDL-1 positive EAC after progression on standard tx: Pembrolizumab as per KEYNOTE-028 Study: adverse effects and discontinuation?

Answer 2

54% AE: fatigue, pruritus, pyrexia, \appetite 20-17-13-13%

No grade IV AE nor discontinuations

Question 3

Molecular classification of 1040 EAC tumors from GOG 210: frequency of classes and recurrence rate for CNA?

Answer 3

49% CNS (copy number stable-low)
39% MMR deficient
8% CNA (copy number altered-high-p53m): 19% mortality and 37% 🔄 rate
4% POLE: / OS

Question 4

Outcome of PORTEC-3 study according to cases reclassified according to TCGA categories?

Answer 4

TP53 aberrant tumors - RFS with chXRT>XRT

POLE pts had excellent RFS regardless of tx modality